John S. Fleming

John S. Fleming

Auto-generated profile, based on publicly available information

John S. Fleming

National Institute of Health Research Biomedical Research Unit in Respiratory Disease , Southampton, United Kingdom

Research Focus & Metrics

Academic Career Length

54Years (1973-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
JFJohn S. Fleming
John S. Fleming
MZMaureen A. Zivanovic
Maureen A. Zivanovic
GBGlen M. Blake
Glen M. Blake
MBMaria Burniston
Maria Burniston
PCPhilip S. Cosgriff
Philip S. Cosgriff
These guidelines have been adopted by the British Nuclear Medicine Society.

21 July 2006 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
LTLivia Tossici-Bolt
Livia Tossici-Bolt
SHSandra M. A. Hoffmann
Sandra M. A. Hoffmann
PKPaul M. Kemp
Paul M. Kemp
RMRajnikant L. Mehta
Rajnikant L. Mehta
JFJohn S. Fleming
John S. Fleming

1 January 1979 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
JFJ S Fleming
J S Fleming

1 June 2003 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PKP M Kemp
P M Kemp
CHC Holmes
C Holmes
SHS M A Hoffmann
S M A Hoffmann
LBL Bolt
L Bolt
RHR Holmes
R Holmes
JFJ S Fleming
J S Fleming
Objective: To compare the HMPAO SPECT cerebral perfusion patterns in early and late onset Alzheimer’s disease. Methods: Twenty patients with early onset disease (65 years) were studied. All patients fulfilled NINCDS-ADRDA clinical criteria and had details of disease severity and length of history at the time of imaging. Technetium-99m HMPAO SPECT brain scans were acquired on a multi-detector gammacamera and analysed visually and with statistical parametric mapping (SPM99). Results: Patients with early onset disease had significantly greater posterior cortical association area involvement whereas those with late onset disease had significantly greater medial temporal hypoperfusion. These findings were unchanged after controlling for disease severity and length of illness. Discussion: These functional imaging findings of the differences between early and late onset Alzheimer’s disease are supported by published findings that include histopathological and clinical evidence; namely late onset patients tend to present with the characteristic involvement of the medial temporal lobes producing marked memory loss whereas early onset patients present with predominant posterior cortical association area involvement. These age related findings should be borne in mind when clinically diagnosing, and interpreting functional brain imaging studies in, patients with suspected Alzheimer’s disease.

1 February 1989 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
JFJ. S. Fleming
J. S. Fleming
A technique is described for using computed tomography (CT) images for attenuation correction and quantification in SPECT. The CT images are aligned with the corresponding SPECT slices and the Hounsfield units are converted to linear attenuation coefficient values for the SPECT radionuclide. The attenuation coefficient map thus produced is used to provide the attenuation correction required in the SPECT reconstruction. The technique has been evaluated in both a non-anatomical and an anatomical phantom giving a mean accuracy in quantifying activity of various features in the phantoms of 2.6% (range 0.3%-4.0%). The value of performing scatter correction prior to attenuation correction in obtaining accurate quantification is demonstrated. The practicalities of applying the technique in patient studies are discussed.

1 December 2012 in Journal of Aerosol Medicine and Pulmonary Drug Delivery
Verified
Journal Article
Closed access
SNStephen Newman
Stephen Newman
WBWilliam D. Bennett
William D. Bennett
MBMartyn Biddiscombe
Martyn Biddiscombe
SDSunalene G. Devadason
Sunalene G. Devadason
MDMyrna B. Dolovich
Myrna B. Dolovich
KZKirby L. Zeman
Kirby L. Zeman
Two-dimensional (2D or planar) imaging with 99mTc radiolabels enables quantification of whole-lung and regional lung depositions for orally inhaled drug products. This article recommends standardized methodology for 2D imaging studies. Simultaneous anterior and posterior imaging with a dual-headed gamma camera is preferred, but imaging with a single-headed gamma camera is also acceptable. Correction of raw data for the effects of gamma ray attenuation is considered essential for accurate quantification, for instance, using transmission scanning with a flood-field source of 99mTc or 57Co. Evidence should be provided of the accuracy of the quantification method, for instance, by determining “mass balance.” Lung deposition may be expressed as a percentage of ex-valve or ex-device dose, but should also be given as mass of drug when possible. Assessment of regional lung deposition requires delineation of the lung borders, using X-ray computed tomography, radioactive gas scans (133Xe or 81mKr), or transmission scans. When quantifying regional lung deposition, the lung should be divided into outer (O) and inner (I) zones. A penetration index should be calculated, as the O/I ratio for aerosol, normalized to that for a radioactive gas or transmission scan. A variety of methods can be used to assess lung deposition and distribution. Methodology and results should be documented in detail, so that data from different centers may be compared. The use of appropriate methodology will provide greater confidence in the results of 2D imaging studies, and should allay concerns that such studies are qualitative or semiquantitative in nature.